New York, NY -- (SBWIRE) -- 12/18/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: National Bank of Greece (ADR) (NYSE:NBG), Geron Corporation (NASDAQ:GERN), New Gold Inc. (USA) (NYSEMKT:NGD), Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)
National Bank of Greece (ADR) (NYSE:NBG) showed a volume of 3.35million shares by the end of last trade whereas the average volume of the stock remained 3.25 million shares. The stock opened the session at $5.73 but then moved to $5.70. At that price, the stock showed a negative performance of -2.06%. National Bank of Greece SA (the Bank) is a Greece-based financial institution. It provides a range of financial services including retail and commercial banking, asset management, brokerage, investment banking, insurance and real estate at a global level. Its segments are: Retail Banking, which mainly offers different types of loans, deposits and investment products; Corporate and Investment Banking, which includes financial and investment advisory services, deposit accounts, loans, foreighn exchange and trade service activities; Global Markets and Asset Management,
Will NBG Get Buyers Even After The Recent Rally? Find Out Here
Geron Corporation (NASDAQ:GERN) opened the session at $4.81 and closed the session at $4.70. The stock showed a negative performance of -2.99% in previous trading session. Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML).
Has GERN Found The Bottom And Ready To Gain Momentum? Find Out Here
New Gold Inc. (USA) (NYSEMKT:NGD) opened the session at $4.79 and closed the session at $0.276. The stock showed a negative performance of -0.62% in previous trading session.The beta of the stock remained 0.03. New Gold Inc. is engaged in gold mining and related activities, including acquisition, exploration, extraction, processing and reclamation. Its operating assets consist of the Mesquite gold mine (Mesquite Mine) in the United States, the Cerro San Pedro gold-silver mine (Cerro San Pedro Mine) in Mexico, and the Peak gold-copper mines in Australia. It also consists of exploration and development projects, which include the New Afton copper-gold project in Canada, a 30% interest in the El Morro project in Chile and the Blackwater project in Canada.
Why Should Investors Buy NGD After the Recent Fall? Just Go Here and Find Out
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) the stock advanced 5.85% and finished the session at $2.17. The beta of the stock remained 0.60. Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company’s radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent.
Will NAVB Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)